Description
Dosage of erythropoietin stimulating agent has been reduced and maintained in response to hematocrit or hemoglobin level.

Guidelines/Instructions
This modifier is used for national claims monitoring for ESAs administered in Medicare renal dialysis facilities, so therefore, is not applicable to Part B.

Reference: CMS Medicare Claims Processing Manual (Pub. 100-04), Chapter 8, Section 60.4 (PDF, 1.82 MB).

Contact Palmetto GBA JJ Part B Medicare

Provider Contact Center: 877-567-7271

Email JJ Part B

Contact a specific JJ Part B department


Click to Chat Now